Skip to content

塞尔库伊蒂

US · CELC #2398 按市值排名 上市于 2017
56.58 -3.72 -6.17%
实时 - 追踪5344个代码 - 心跳于341秒前 · 2026-10-16 20:02

估值 各估值倍数与自身5年区间的对比

市净率 -272.99 低于历史水平 第3百分位
5年平均 4.87
市盈率 -16.57 低于历史水平 第20百分位
5年平均 -9.52 · 前瞻 -15.21
市销率 --
5年平均 0.00 · 前瞻 29.90

同业对比 Biotechnology

公司 市值 市盈率(TTM) 市净率 股息率
塞尔库伊蒂 (CELC) 2.77B -13.16 -216.78 0.00%
Vertex Pharmaceuticals (VRTX) 126.66B 29.11 6.26 0.00%
Moderna (MRNA) 87.04B -27.32 12.87 0.00%
Regeneron Pharmaceuticals (REGN) 81.41B 19.57 2.57 0.46%
argenx SE (ARGX) 51.51B 31.21 6.12 0.00%
BeiGene (ONC) 41.96B 65.32 8.11 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值74.23 经济护城河None 不确定性Very High

当前股价低于晨星合理价值估算31.2%。

合理价值

Celcuity Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a price consistent with our quantitative fair value estimate, which has a very high uncertainty rating.

The firm's balance sheet bolsters our fair value estimate. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio of 8.9 ranks in the top 10% compared with global peers. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our balanced fair value estimate.

Conversely, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of -0.4%, a core component of valuation, ranks in the bottom 10% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our neutral price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is fairly-valued, this outperformance had a negative impact on our valuation estimate.

经济护城河

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 20:02:25 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

塞尔库伊蒂 讨论区 0 条评论

发表评论